title: Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration.
abstract: The purpose of this study was to characterize changes in the levels of insulin-like growth factor-I (IGF-I) and IGF binding proteins (BP) 1, 2, and 3 in HIV-infected adults throughout the course of their disease, and to assess the responsiveness of the IGF system components to growth hormone (GH) administration (6 mg/day) for 2 weeks. Healthy control study subjects (n = 10) were compared with patients who were either HIV-positive (n = 9), had AIDS without weight loss (n = 13), or had AIDS with >10% weight loss (n = 6), all of whom had been free of acute illness for at least 3 months. Under basal conditions, fasting serum concentrations of epinephrine, norepinephrine, cortisol, glucagon, insulin, IGF-I, and IGFBP-3 were not significantly different among the four groups. The serum concentrations of IGFBP-1 and IGFBP-2 were significantly higher in AIDS patients with wasting than in the other three groups (p < .05). In addition, there was a statistically significant positive correlation between the levels of IGFBP- 1 (p = .004) and IGFBP-2 (p = .03) and the stage of disease. Following GH administration, the serum concentrations of insulin and IGF-I were increased in all groups (p < .05). In addition, the increases in insulin levels correlated with stage of disease (p = .004). The responses of the IGFBPs were more variable. GH administration significantly increased the levels of IGFBP-3 in all groups except the patients with AIDS wasting, whereas the levels of IGFBP-1 were significantly decreased in controls and AIDS patients. These results demonstrate that there is a continuum of both elevations in the IGFBPs and altered metabolic responsiveness in patients infected with HIV that increases with the severity of the disease. These data also demonstrate that AIDS patients, who are free from secondary infection, respond to administration of GH by significantly increasing hepatic IGF-I production.
authors.affiliation: Department of Medicine, State University of New York at Stony Brook, 11794-8154, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Mynarcik
authors.forename: R A
authors.initials: RA
authors.lastname: Frost
authors.forename: C H
authors.initials: CH
authors.lastname: Lang
authors.forename: K
authors.initials: K
authors.lastname: DeCristofaro
authors.forename: M A
authors.initials: MA
authors.lastname: McNurlan
authors.forename: P J
authors.initials: PJ
authors.lastname: Garlick
authors.forename: R T
authors.initials: RT
authors.lastname: Steigbigel
authors.forename: J
authors.initials: J
authors.lastname: Fuhrer
authors.forename: S
authors.initials: S
authors.lastname: Ahnn
authors.forename: M C
authors.initials: MC
authors.lastname: Gelato
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000503:physiopathology; D000328:Adult; D016022:Case-Control Studies; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D015658:HIV Infections / Q000503:physiopathology*; D019247:HIV Wasting Syndrome / Q000503:physiopathology; D019382:Human Growth Hormone; D006801:Humans; D007267:Injections; D007328:Insulin / Q000097:blood; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D012646:Self Administration; D015431:Weight Loss
chemical_list: D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D018971:Insulin-Like Growth Factor Binding Protein 2; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone